Glanders, a disease caused by the microorganism Burkholderia mallei, was originally described around 425 B.C. and has been a world problem throughout most of recorded history. Humans can acquire the disease from infected animals by inhalation of the organism or through breaks in the skin. Human disease has been described as "loathsome" (15) and is characterized by purulent abscesses in infected tissues and organs (12) . While B. mallei has seemingly been eradicated from many parts of the world today, its classification as a category B biothreat agent suggests that the microorganism could have a significant negative worldwide impact on human health. No vaccines against glanders exist, and current diagnostic tests cannot discriminate between infections caused by B. mallei and those caused by Burkholderia pseudomallei, another category B pathogen (8) . Antibiotic therapy is usually successful with timely diagnosis of the disease.
The relative importance of humoral antibodies and cellmediated immune responses in glanders immunity remains to be elucidated. Attempts to passively transfer immunity with immune serum were unsuccessful (10, 17) . Published reports appear to suggest a greater role for cell-mediated immunity than humoral immunity in the limitation of the early spread of B. mallei in the host (5, 6) . Irradiated B. mallei induced a Th1-and Th2-like cytokine response and a Th2-like subclass immunoglobulin response in BALB/c mice (1). Interleukin-12 (IL-12) has been shown to enhance protective immunity against glanders. Vaccinating mice with irradiated B. mallei plus IL-12, but not irradiated B. mallei alone, appears to induce partial protective immunity against a lethal subcutaneous challenge with B. mallei (K. Amemiya, personal communication). Injecting plasmid DNA encoding IL-12 in mice to induce in vivo expression of the cytokine resulted in a significant protection against aerosol infection with B. mallei (R. Ulrich, personal communication). An attenuated branched-chain amino acid auxotroph mutant of B. mallei was recently shown to partially protect against aerosol infection in mice (16) .
In an attempt to generate specific antibodies that could be useful in the specific diagnosis of glanders and in prevention of disease, monoclonal antibodies (MAbs) were generated in BALB/c mice. In determinations of antibody specificity or efficacy against infection, results were evaluated for statistical significance by linear regression analysis or by analysis of variance. Survival distributions were compared by Kaplan-Meier methods. All tests were at the 95% confidence level (two tailed) (14) .
To generate monoclonal antibodies, mice were injected intraperitoneally (i.p.) with 100 g of irradiation-killed mid-logphase B. mallei China 7 strain (ATCC 23344) cells and given a second injection 14 days later. Three days after the booster injection, a splenocyte suspension was prepared from the mouse with the highest enzyme-linked immunosorbent assay titer against B. mallei and fused with the murine myeloma cell line P3X63-Ag8.653 (7) . Primary hybridoma culture supernatants were screened for antibody activity by enzyme-linked immunosorbent assay with irradiated B. mallei-or B. pseudomalleicoated microtiter wells, and B. mallei-positive hybridomas were subcloned by limiting dilution. Thirty-two clones reacted with B. mallei antigens and were selected for further specificity screening (data not shown). Of these, four anti-B. mallei clones were finally selected, based on their strong reactivity with B. mallei and absence of reactivity with the closely related B. pseudomallei (8) . Antibodies were purified by protein A chromatography; purity was assessed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Culture supernatants from the four selected hybridomas, designated 1G2-1D3, 1G3-1, 9C1-2, and 8G3-1B11, reacted with B. mallei even at high dilutions of culture supernatants tested (Table 1 ). At each dilution tested, absorbencies of microtiter wells coated with B. mallei antigens were significantly greater (P Ͻ 0.003) than absorbencies of microtiter wells coated with B. pseudomallei antigens.
To determine the ability of the anti-B. mallei MAbs to specifically capture B. mallei antigens in solution, B. mallei or B. pseudomallei cell lysates were added to microtiter wells precoated with individual anti-B. mallei MAb. Antigen capture was detected by adding a heterologous anti-B. mallei MAb conjugated to biotin ( Table 2 ). All four anti-B. mallei MAbs
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Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. (11) . The immunoblot reactivity of two representative MAbs (8G3-1B11 and 1G2-1D3) is shown in Fig. 1a . Both MAbs reacted with B. mallei antigens characterized by a typical LPS ladder-banding pattern, ranging from approximately 20 kDa to 50 kDa in molecular mass (Fig. 1a, lanes 1  and 2) . No reactivity was detected in immunoblot analyses of irradiated B. pseudomallei separated by SDS-PAGE (data not shown). Pretreating the irradiated B. mallei bacterial lysate with proteinase K did not abolish nor alter the immunoblot reactivity or the typical ladder-banding pattern, further supporting the lipopolysaccharide (LPS) nature of the antigens recognized (Fig. 1b, lane 2) . Again, no immunoblot reactivity was evident with irradiated B. pseudomallei bacterial lysate (Fig. 1b, lane 1) . Ample experimental evidence exists to suggest an important role of bacterial capsules in the virulence of both gram-negative and gram-positive pathogens. The capsular exopolysaccharide of B. mallei and B. pseudomallei was recently demonstrated to play a vital role in enhancing the virulence of the bacteria (4, 13). Whether or not the anti-B. mallei MAbs described herein are specific for LPS associated with the bacterial capsule remains to be determined.
We were interested in determining whether our MAbs could passively protect mice against a lethal aerosol challenge of B. mallei. Groups of six BALB/c mice each were injected i.p. with 1.0-mg/mouse of purified anti-B. mallei MAbs and challenged by whole-body aerosol 18 h thereafter with 20 50% lethal doses (LD 50 ; 1.9 ϫ10 4 CFU) of an overnight culture in mid-log phase of B. mallei, strain China 7 (ATCC 23344). Negative control groups were injected with either Hanks' balanced salt solution or MAb F1-04-A-G1 specific for the F1 antigen of Y. pestis. After challenge, the mice were observed daily, and mortalities and the mean time to death were recorded. At the end of the experiment, all survivors were humanely killed. Immunization and challenge experiments were conducted in biosafety level 3 (BSL3) and BSL4 environments, respectively. As expected, the negative control F1-04-A-G1 did not protect the mice from the challenge (Fig. 2) . Conversely, the anti-B. mallei MAbs provided significant protection. Monoclonal antibody 1G2-1D3 completely protected the mice against aerosol challenge (100% survival). Significant protection was also observed in mice treated with MAbs 9C1-2 and 1G3-1 (83% survival). All protected mice survived up to 14 days postchallenge, at which time the experiment was terminated. There were no significant differences in the ability of the MAbs to protect from death (P Ͼ 0.05). All MAbs were able to significantly protect against death (P Ͻ 0.01), compared to the irrelevant MAb control (F1-04-A-G1).
To assess the immunotherapeutic potential of the anti-B. mallei MAbs, groups of six mice each were treated with 1 mg of 1G2-1D3 anti-B. mallei MAb either 18 h before or 18 h after aerosol challenge. Treatment with 1G2-1D3 MAb 18 h before challenge again completely protected the mice against a lethal B. mallei aerosol challenge (P Ͻ 0.001) (Fig. 3) . However, this anti-B. mallei MAb administered 18 h postchallenge was ineffective in providing protection (P Ͼ 0.05). All mice in this group, as well as those in the negative MAb (F1-04-A-G1) control group, died 4 days postchallenge.
This represents, to our knowledge, the first demonstration of passive protection against B. mallei infection in a murine model of aerosolized glanders by MAbs. Note that although significant passive protection was achieved, the spleens of all surviving mice killed at the end of the experiment contained significant numbers of B. mallei cells. Thus, the immune protection mediated by anti-B. mallei MAbs was not sterile but appeared to result from an antibody-induced reduction of the number of infecting pathogens below the lethal threshold. Whether antibody administered Ͻ18 h postchallenge would provide protection remains to be determined. It is clear that antibody-mediated protection is most effective during the initial phase of infection, presumably by clearing the pathogens from the circulation and/or limiting or reducing the number of pathogens being internalized by the primary host target cells, the macrophages. A likely explanation for the lack of protection by MAb treatment administered 18 h postchallenge is that once phagocytosed, the intracellular pathogens are protected from and therefore less affected by circulating antibodies, at robust and specific cell-mediated immunity would in all likelihood be necessary for eliminating infected cells and controlling pathogenesis.
